Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
1. A method of lowering LDL-C in a subject in need thereof, the method comprising administering 180 mg 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and 10 mg Ezetimibe to the subject, wherein the subject has familial hypercholesterolemia.
2. The method of claim 1 , wherein the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe are administered to the subject as a fixed-dose combination.
3. The method of claim 1 , wherein administering the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe decreases the level of C-reactive protein (hsCRP) in the subject.
4. The method of claim 1 , wherein administering the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe reduces the very low density lipoprotein in the subject.
5. The method of claim 1 , wherein administration of the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe reduces the risk of a cardiovascular disease in the subject.
6. The method of claim 1 , wherein the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe are administered once daily to the subject.
7. The method of claim 2 , wherein the fixed-dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is formulated to be a tablet.
8. The method of claim 1 , wherein the subject is human.